Podcasts about Roux

After 128 programs in 2023, our podcast of the year goes to Sofie Roux. Sofie is 19 years old and is wise for her age. Sofie has a "condition of the heart" that started with helping students in Malawi. How can a person use the tools they have to help others, especially those without electricity and basic needs? Sofie poses the question- how can we create and innovate to help the future world, especially for young women? Perhaps being significant starts with a design mentality. Learn more about Bloombox Designs. at www.bloomboxdesignlabs.com.Become a supporter of this podcast: https://www.spreaker.com/podcast/success-made-to-last-legends--4302039/support.

durée : 00:02:44 - L'écureuil roux est la star de l'hiver en Vaucluse pour 3 bonnes raisons ! - par : Nathalie Mazet - Avec sa queue touffue et son allure vive, l'écureuil roux est l'une des mascottes les plus adorables de l'hiver. En ce moment, il est plus facile que jamais de l'apercevoir. Nourriture, période des amours, nids visibles… on vous donne nos conseils de pro pour l'observer facilement ! Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before any of your favorite gym bros were talking about Retatrutide. We were talking about Reta, who tried Retatrutide here at On The Pen. And that's because we identified this triple agonist as a game changer among game changers. So This is going to be a very Retatrutide heavy episode, and so I hope you'll join us and stick with us if this is a topic you enjoy, because I think this is really going to effectively lay the groundwork for what accessibility to this medication will look like. So let's get into it. Welcome to the On The Pen Podcast with your host, Dave Knapp. Welcome to the On The Pen, the weekly dose podcast. This is our weekly roundup in incretin memetic news. And frankly, there's no news that is bigger than Reta-Trutide news. Just find me any news that is bigger than the data that we got on Reta-Trutide. Now, we already did a video about the Triumph Phase II clinical trials that we got in osteoarthritis of the knee. You can go back and check out that video if you'd like more data. So we're not gonna super... rehash the data. We'll go over at a high level what the data showed us. We're not going to go over how the medicine works, because by now we all know that it's the triple agonist, right? If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat. It is absolutely revving up people's metabolism and showing a tremendous amount of weight loss. So let's get into what the weight loss looked like in this first trial, because there are longer obesity trials where, where the primary outcome is the weight loss this was again a specific trial in measuring pain reduction in folks with osteoarthritis of the knee but check out these numbers these are placebo adjusted meaning it's taking the two percent out that people lost on placebo but looking at these numbers Folks on one milligram over forty eight weeks lost seventeen percent. They bumped up to four milligrams. Those folks lost twenty two percent. So right there at the lowest dose, you're already reaching the efficacy of today's drugs that are on the market, like triseptide and semaglutide in their various forms. If you bumped up to eight milligrams, you saw twenty four percent placebo adjusted weight loss and at twelve milligrams, twenty six point four percent weight loss. Adding back in that two percent of the placebo that those on placebo loss, that's twenty eight point four percent weight loss in these forty eight weeks at the highest dose. When you adjust for some of the more real world outcomes, you kind of ding the numbers a little bit based upon people who quit the drug, et cetera. Those numbers look more like a twenty percent weight loss and twenty three point seven percent weight loss at the highest dose. But even then, you're still seeing a drug that is better than the current drugs that are on the market. around forty eight percent of patients on Retatrutide lost greater than twenty five percent. And then if you were at that twelve twelve milligram dose, that highest dose patients lost fifty nine percent of patients lost more than twenty five percent of their body weight. There was a subset that lost thirty percent of their body weight and some even over thirty five percent of their body weight on Retatrutide. So the lower doses compete with today's best drugs and the upper doses are entering into bariatric surgery level weight loss. And that's putting the whole obesity system on notice and probably a lot of surgeons nervous because typical body weight loss was something like the street sleeve gastrectomy. For example, it's about eighteen to twenty five percent body weight. The Roux-en-Y gastric bypass twenty five to thirty five percent weight loss or the duodenal switch thirty to forty percent weight loss. So the upper doses of Ritutrutide overlap with sleeve and bypass outcomes without any surgery. It's incredible. It is a game changer among game changer. It is the new benchmark in obesity medicine. And there's actually more data, like I said, landing in later twenty twenty six. The longer duration will historically, if history is a marker, equal more weight loss than we even see here at this forty eight weeks. We have an interview that will be airing later this week on our channel and on our podcast with our friend Mimi from Australia who just wrapped up her clinical trial on Retatrutide. They ended it like ten weeks early on her, which was a huge bummer to her. So we're going to hear from her because she had to end abruptly. We're going to hear her story, an incredible story. She's one of those folks that got up that thirty five percent body weight loss in the time that she was on Retatrutide. So, this is just showing you that these drugs are not simply an alternative to bariatric surgery. We are approaching a point in time where these are on par with bariatric surgery, and as people are on this Reta-Trutide trial, you see that these numbers aren't plateauing either. So we will see stronger weight loss numbers the longer that these folks are on this trial. And I think you'll see some of those numbers in that population of folks on the higher doses eclipse maybe even some of what we see with some of these bariatric surgeries. the real story that i think is taking shape here is not in how powerful Retatrutide is because we've literally been expecting or anticipating this kind of data for more than three years at on the pin we've been talking about this and i think that's sort of reflected in the fact that you didn't see this massive spike in eli lilly stock wall street was expecting this as well Um, so it was on par, I think with expectations, but the expectations are astronomical compared to previous options that were available to patients and all the innovation in the world. All of these drugs, we talked at last week about WV, E double Oh seven, the James Bond of weight loss that targets fat, not only targets fat loss, but it also targets the promotion of building of, of lean muscle mass. We're talking about an insane future in obesity medicine. But none of it means anything if people can't access it. And that's really where we are today in terms of ensuring that there's going to be an option for everyone. And that's sort of what I want to get into today, because Lilly wants Retatrutide to be classified as a biologic, so not a traditional small molecule drug like you've seen every other incretin and nutrient-stimulated hormone-treating obesity on the market to date. They're trying to get this classified as a biologic. Now, we talked about this before on the podcast. That matters in three major ways. It affects the exclusivity length of time that a pharmaceutical company has on a drug. That goes from, I believe, five years of market exclusivity to twelve. It affects compounding rules because biologics cannot be compounded. And then that gives the pharmaceutical companies a tremendous amount of pricing power in the marketplace, because essentially there's no competition and there's no competition for a long time. But this whole argument about getting this classified as a biologic is not about safety. It's about protection and we're going to get into it. So let's explain this here. This is why Retatrutide really is not a biologic arguably. So biologics are large proteins. There are hundreds of or even thousands of amino acids grown in living cells that are sensitive to tiny manufacturing changes. Retatrutide is a short chain peptide. It's chemically synthesized and it is below the traditional biological size thresholds when it comes to how those things are defined. We'll just leave it at that. So even though it acts like a biologic in the body, it's made like a drug. It's made like a small molecule drug. And if it's treated as a drug, they get, like I said, five years of market exclusivity. Now, really a lot of confusion around what this means, but essentially the first five years of the life of a drug, the patent can be challenged for a number of reasons. We've seen patent challenges right now are going on in the courts for both semaglutide and terzepatide. But these companies are guaranteed that five years of market exclusivity, no matter how those patent lawsuits shake out. That five years jumps to twelve years with the biologic. So ultimately, there's no biosimilars that are allowed during that twelve year window. Again, with terzapatidin and semaglutide, it's five years. They could lose their market exclusivity within five years of the release of the patent. twelve years with a biologic. So if they lose their patent challenges on Trezabitide, they still have some time left with market exclusivity for the drug. They likely will not lose those, but that jumps to twelve years. And I think the most important thing to understand about the reclassification of Reta-Trutide to a biologic would mean that, 503A and 503B pharmacies are effectively locked out of compounding this medication, 503Bs would have some latitude arguably, but they would face extreme barriers. Routine compounding becomes legally and technically restricted because biological status doesn't slow compounding down. It actually shuts the door or almost completely shuts the door. Biologics not only would allow Lilly to have longer market exclusivity, no compounding, but it would allow them to command a higher price in the marketplace because A, they get this designation and there's an assumption when they bring this to market that they're harder to manufacture, that they're harder to copy, that there are fewer negotiating alternatives for payers. They can command a higher price with the insurance companies, and the price pressure stays muted for much longer because, again, you don't have those pressures of compounding. You don't have the pressures externally from lawsuits that could end your market exclusivity in that first five years of the drug's existence. So there's just a lot of price pressure upwards on a biologic compared to a normal small molecule drug. And when there's no credible alternative or backup option, which to Retatrutide, there wouldn't be, it'd be the first drug that has bariatric surgery level results. The prices won't come down. They'll command a massive price and the prices won't come down. So let's talk about where this currently stands because ultimately the Eli Lilly went to the FDA. We've been covering this for well over a year, maybe close to two years now, a year and a half at least. Lily went to the FDA, they said, we want this classified as a biologic, here are the reasons why. The FDA initially said, no, we're not gonna do that. So Lily challenged that decision in court. So the point that we're at today is the court told the FDA to reconsider and better explain itself So the first no given to the FDA to Lilly didn't stick. The courts looked at it and they said, you need a better, you need to reconsider your decision and you need to explain your decision better to Lilly. So ultimately we're sitting now at the point where the court has made its decision that the FDA has to go back and now we await basically what the FDA has to say on this. But if this thing is classified as a biologic, that would be a massive massive loss for patients. Now, again, we're, we're focusing on the accessibility of this drug into the future. And, and I think that this is an important conversation to have. One of the interesting points that I have to bring into the conversation is the fact that I got to sit in on a, on a closed session question and answer with the media. I didn't get to answer or, excuse me, excuse me, ask a question at this time, but shortly after the most favored nations announcement, with eli lilly and the trump administration in the oval office that day there was a press briefing that i was invited to dave ricks was asked by max bayer reporter of endpoints who we've interviewed here on this very podcast and he was asked was Retatrutide included in the most favored nations discussions meaning will we get a cash pay version of Retatrutide uh that is you know circumventing the pbms uh will we get these cheaper prices will will it be be two hundred fifty dollars also and there was a hard no there was a hard no like no that was not included that was not part of these discussions even though what we heard from the trump administration was that those these companies that were jumping on to the most favored nations agreement were also agreeing to offer future drugs at most favored nations pricing now was lily saying that no they're not going to offer it at the it wasn't part of the negotiations in terms of the price points that they had discussed for triseptide maybe or did it mean altogether there won't be a cash pay option of this medication i don't know um that we would love to get clarity on But I highly doubt we're going to get any more information than necessary at this point in time. So, Reta-Trutide is being positioned to be a drug that, and well so, should be offered at a premium. This is a drug that is far exceeding the current drugs that are on the market. I think that we're gonna see even the indications of Reta-Trutide far beyond simple obesity, but it is going to be their crown jewel for the next decade, more than likely. Reta-Trutide is going to be a massive drug, and so they're attempting to build a moat around it. And these are things that we need to be aware of as a community so that we can hold our positions and conversations about these and basically, you know, be able to articulate to people in positions of power like this is an important thing to us. This is an important thing in the advocacy of obesity and sort of the next frontier of the fight of accessibility, which marches on. each and every day because of course the current drugs, while as great as they are and as much as access is expanding, there are still people with sicker or rather more advanced versions of metabolic disease that are gonna need these newer treatments and price is going to be a huge factor. So let's talk about the gray market right now because I think it's also nearly impossible to talk about this topic without including a discussion about the gray market because there are, as I mentioned at the outset, hundreds of thousands of people on this medication already. So research grade Retatrutide exists. It's in the gray markets of the Internet. It's where people are going and they're buying, you know, basically versions of these these peptides that are made in factories overseas. They're being imported into the United States, oftentimes illicitly in shipments that are marked as something else. The FDA has tried to crack down. There's no doctor involved in this. It's a very, that's why it's called the gray market, right? So it's not a prescription medicine, but the demand for this is massive. And all you have to do is really scroll your TikTok for about fifteen minutes. You're going to come across a insane amount of content on the topic of Retatrutide. An insane amount of, and oftentimes, you know, what I find most disturbing is oftentimes it looks like very young people. very young people taking Retatrutide. Crazy, it's crazy. But the demand is massive and there's a whole gray market for it proliferating over on TikTok and in the far reaches of the internet. And I would estimate that tens, if not hundreds of thousands of people are already or have already used it. And I think it's a testament to a to to the effectiveness of this drug. It's also a testament to the fact that there needs to be more guardrails, I think, around this stuff than there currently is, because gray markets appear and they thrive when legal access lags the reality of the demand for the medication. And you saw this earlier this week as we launched a petition to fight back against the Safe Drug Act of twenty twenty five, a drug, a drug act that is in theory designed to put guardrails around compounding. But in practice, I think is creating a new battlefield for Eli Lilly and Novo Nordisk to shut down compounding on the current classes of medications, which is why We as a community need to be loud about our opposition to it. If they were really concerned about the safety of compounds, they would do two very simple things. They would require reporting around the active pharmaceutical ingredient of a compound. Patients ought to be able to know where the actual source of their medication is coming from. And they should know that those places are FDA approved and inspected. And the second thing is they should require adverse event reporting. Those are required of 503Bs. They should be required of 503As as well. 503As are making a tremendous amount of money. They're making thousands and thousands of these scripts. So when there are adverse events, they should be required to report those to the FDA. Simple. None of that is in this bill. None of it. None of it. Instead, it seeks to put caps on the amount of compounds that can be made by a compound pharmacy without them having to report to the FDA. And then it seeks to codify the definition of essential copy. Again, all of these things that will become law and then argued in court and then a battlefield for Lilly to potentially win a legal battle and thwart compounding. It's creating a new battlefield for them. They're losing in the courts. They're losing with the current language that exists in the Food, Drug, and Cosmetic Act. So we create new language. We create new law. Just vague enough to pull some threads and hopefully win something in court. That's how I see it. You may see it differently. If you do, curious to hear from you. But if you want to fight back against this legislation, you can go to otplinks.com and fight back against that. piece of legislation, because I think that we need as a community to have our voices heard on this, especially those who have gotten healthier by way of compounded medications. So the rumor on the gray market, to get back and close the thought loop here, There's been no specific FDA cutoff announced, but what the rumors going around are that that the compounded versions of GLP ones, especially obesity medicine in the gray market, are all going to turn off like a sieve on January first. Now, I seem to feel like this is probably more of a marketing tactic by these companies to sell a whole bunch of peptides at the end of the year. I think that's probably creating some panic and probably panic buying on people's parts. And so these companies are benefiting greatly. Again, that's why there should be guardrails around this. There's no guardrails around this at all. I mean, at the end of the day, they can say whatever they want to say, so long as they cloak everything in research grade. And these rumors proliferate around and people spend thousands, tens of thousands of dollars. I've heard of people having twenty years worth of Retatrutide in their freezer. Why? For what purpose do you need that? So just a massive amount of money made in this gray market. And that's not to knock people who use it. I say this all the time, but I think it's worth qualifying the statement. It's not knocking people who use it. I get it. But at the same time, we're talking about an industry that is, there's no altruism here. They're in it for money just as much as Eli Lilly is, except they have actually done nothing in the way of advancing medicine. They've just taken intellectual property, copied it, and sold it to you with a label that says, don't put this in your body. So you know where I stand on the gray market. I've heard from many people who've been injured by gray market stuff. It's just what it is. It's a gray market. You're taking your health into your own hands. Please, whatever you're doing out there, as risky as it may be, please involve your doctor and let your doctor know what you're doing so you can be monitored for the things your doctor believes you should be monitored for if you're using this. But this all underscores, again, the need for accessibility to these medications, the need for us to be aware of the fact that a moat is already being built around the most advanced metabolic drug in the pipeline. And we just need to be aware so that when it comes time to fight, we're all ready and informed. And that's what this podcast is serving to do. Before we jump into the next topic, I do want to thank our sponsor, our headline sponsor of this podcast. is a company called Shed. Now, if you are looking for access to care for obesity, then look no further than our partners at Shed who believed in this podcast enough to help us do it full time. You can go to Trished.com and use code OTP25 to save twenty five percent at Trished.com, where you're going to get connected to a doctor who will when medically necessary prescribe medication to treat your obesity. You also get access to coaching. You'll get access to all sorts of medication, whether it's the branded or the compounded versions, depending on your specific situation. All of it is available at Trished.com. They use one of my favorite compound pharmacies in the game, Strive Pharmacy, which I've gotten the chance to dig into on my own. I really love what they do there. They're a It functionally operates a lot more like a 503B. Uh, and I think that they're doing great work over at a strive pharmacy. They partner with shed. So I just love this, this, and when we were looking for somebody to offer a compounded versions, I wanted to make sure that I trusted the pharmacy. People always ask me, Dave, who, who should I go to? I'm like the pharmacy matters more than anything because you want to trust the source of your medication. So try shed.com use code OTP25. Listen, you're going to want to learn about taking any new medication before you take it. Learn about the potential side effects. Learn about the trade offs. There's no free lunch, but all of the information that you're going to need, you can find it. Try shed.com and be familiarizing yourself with all of your options there. So thank you to Shed for being a wonderful partner here at On The Pen. Now let's talk about some data that dropped. We're talking about accessibility and all of the sort of advancements in the world mean very little if people can't access it. That's why I think this data that dropped this past week from our friends over at Rowe is incredible. Absolutely game changing data. So check out this data. Real world telehealth data looking at sixty eight weeks. This is looking at patients who were enrolled in their row body program and on a GLP one specifically some maglutide mean weight loss in this study looked at again patients in over sixty eight weeks. The mean weight loss was sixteen point six percent on average. Thirty three percent of patients lost more than twenty percent and the safety in this study and looking at this data match the clinical trials. So what we're seeing here is that care for obesity can be delivered through a telehealth platform at scale and match clinical trial results. So that scalability decides how many people get access. There are not enough doctors out there to serve the over hundred million people in the United States living with overweight or obesity. so when you hear these blowhard doctors online calling all telehealth platforms except their own a pill mill or as i like to say pin mill the data is actually showing something quite different in that this type of obesity care can be delivered at scale through telehealth platforms it can meet people where they're at and allow people to get care without the shame, without the stigma, without their doctor just pointing to the door and saying, if you want a GLP-I, get out of my office. I ain't going to get it here. How ridiculous. But these people can go to platforms like Rho or Shed or any number of telehealth platforms that are out there and not only get access to medicine, but get access to care. So of course, not all telehealth companies are created equal. Of course, not all compound pharmacies are created equal. You want to do your homework and all of that. But this is data that shows that This kind of care can be delivered at scale via a virtual platform and show similar results to a clinical trial. I think, and this is peer reviewed data, and I think that this is just absolutely great news because when we talk about the problem, we need scalable solutions. The old brick and mortar ain't going to work when you don't have enough doctors to serve enough patients. If we want to get life-changing treatments like ritatratide or terzapatide, semaglutide, whatever, into the hands of the people who need it the most, we need companies to innovate scalable tech platforms that can meet patients where they are, that can leverage current technologies to find people the care that they need. And in this case, it's access to a doctor. It's access to a platform. It's access to prescription medication when appropriately prescribed. And it can be done, and it is being done. So I think this is great news, and will play a huge part in the future. As we talk about Retatrutide, even though it's a year and a half away, maybe a little bit longer, it's already exposing – the issues around accessibility and pricing. Hopefully there will be compounded versions available if they're medically necessitated, if there are shortages. We hope that the battleground for that is not already set and won by Lilly before this drug even comes to market. But there are strategies being done to keep people boxed out But I can tell you that whatever happens with Retatrutide, the future of obesity medicine is in virtual care. And platforms are rising to the occasion. Retatrutide hasn't reached patients yet, but it's already forcing the system to show us, you know, are you ready? Are you ready to deliver bariatric surgery level results at scale to the people who need them? So I am so thankful that you joined me here on this podcast today. Again, we love to talk about we're at a Retatrutide. If you're interested, we've been going live every Monday, Wednesday and Friday at eleven a.m. Central Time here on our YouTube channel, on our tick tock, on our X platform. We're doing that because there's enough news to bring you just about every single day. And we've been doing it for the last couple of weeks. If you've enjoyed it, let me know in the comments of the video on YouTube. Send me an email at David on the pen dot com. Uh, so every single Monday, Wednesday, Friday, and then we do a weekly rundown of the obesity medicine news every Tuesday. That's what this is. The weekly dose podcast. You can catch this on all of the platforms that you listen to your podcasts on, and please make sure to leave us a five star rating and review before you log out of your podcast app. That helps so much. I don't think you guys understand how much that helps, uh, the work that we do here to just train the podcast algorithms that this one is worth listening to. I hope you enjoyed today's podcast. If you did, drop it a thumbs up, five-star review, subscribe on YouTube, do all the things. Thank you for being here, and thank you for being the best part of what we do. We will catch you on the next one. Thank you, my friends. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Zain Johnson speaks to Marlene le Roux, CEO of Artscape Theatre, about the latest productions, performances and upcoming highlights at the Artscape. Weekend Breakfast with Sara-Jayne Makwala King is the weekend breakfast show on CapeTalk. This 3-hour morning programme is the perfect (and perky!) way to kickstart your weekend. Author and journalist Sara-Jayne Makwala-King spends 3 hours interviewing a variety of guests about all things cultural and entertaining. The team keeps an eye on weekend news stories, but the focus remains on relaxation and restoration. Favourites include the weekly wellness check-in on Saturdays at 7:35 am and heartfelt chats during the Sunday 9 am profile interview. Listen live on Primedia+ Saturdays and Sundays between 07:00 and 10:00 am (SA Time) to Weekend Breakfast with Sara-Jayne Makwala-King broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/AgPbZi9 or find all the catch-up podcasts here https://buff.ly/j1EhEkZ Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Vendredi 12 décembre 2025, toute l'équipe de la matinale de RTL2 s'installe à L'Aronde Riedisheim près de Mulhouse pour une émission exceptionnelle à ne pas manquer. Grégory Ascher, Erika Moulet et toute l'équipe du Double Expresso RTL2 vous ont donné rendez-vous pour une émission spéciale en public et en direct. Les invités du jour - Boulevard des Airs : Le groupe, récompensé par une Victoire de la Musique en 2019, présente son nouvel album "Je rentre à la maison" sorti le 17 octobre 2025. Ils évoquent leur attachement aux racines et leur tournée à venir, qui débutera le 15 janvier à Grenoble et passera par l'Olympia le 18 mars. - Guillaume, potier céramiste : Présent sur le marché de Noël de Mulhouse, il partage sa passion pour la céramique et ses créations uniques, fabriquées à partir d'argile de Dordogne et de Bourgogne. - Sandrine Raymond, responsable de la bibliothèque municipale : Elle parle de la sixième nuit de la lecture sur le thème de Robin des Bois, un événement familial qui désacralise le lieu de la bibliothèque. - Céline de la Biscuiterie Albicère : Elle présente les fameux "Bredala", biscuits traditionnels alsaciens, et parle des ateliers biscuits qu'elle organise. - Solène Roux, directrice adjointe de l'écomusée d'Alsace : Elle décrit le plus grand musée à ciel ouvert de France et ses animations de Noël, notamment le spectacle "Sacrée Lumière". La chanson du jour - Amy Stewart "Knock on Wood" 3 choses à savoir sur Mulhouse - Mulhouse a accueilli Kobe Bryant durant son enfance. - Mulhouse a été un état indépendant jusqu'à la Révolution française. - Le marché de Noël de Mulhouse est solidaire avec une collecte de dons. Le jeu surprise - Nathalie de Mulhouse gagne un séjour au ski à Risoul 1850. La Banque RTL2 - Christophe d'Illzach remporte 1 400 euros. - Nadia de Lille-sur-le-Doux gagne un week-end de détente grâce à Weekend Desk. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

durée : 00:18:50 - Bienvenue chez vous, en cuisine - Depuis 22 ans à Romans-sur-Isère, le truculent Hervé Roux propose une expérience culinaire imprégnée des traditions dauphinoises, mettant particulièrement en valeur les abats de veau, les produits locaux et une cuisine simple mais raffinée, inspirée de ses racines familiales. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

durée : 00:01:47 - Le roux et le caramel au beurre salé Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

La prise en compte institutionnelle ou simplement relationnelle de la souffrance pose des questions abyssales. Dans cet épisode, je reçois la psychiatre et méditante Patricia Roux-Mérot pour une conversation sur les solutions vraiment sérieuses qui l'ont aidée et qui aident ses patients.Pour vous inscrire au webinaire de présentation de la formation à la méditation proposée par Reso : https://formations.reso.co/webinaire-8-dec-2025/Pour découvrir la formation elle-même : https://formations.reso.co/Mon site : https://www.fabricemidal.comFacebook Fabrice Midal : https://www.facebook.com/FabriceMidalFacebook du podcast Dialogues : https://www.facebook.com/dialogues.fmInstagram Fabrice Midal : https://www.instagram.com/fabricemidalInstagram du podcast Dialogues : https://www.instagram.com/fabricemidal_dialogues/Tiktok : https://www.tiktok.com/@fabricemidalMes trois chaînes YouTube :Mes vidéos : https://www.youtube.com/@fabricemidal1Les Dialogues : https://www.youtube.com/@dialoguesfmLes méditations guidées : https://www.youtube.com/@mediteravecfabricemidalMes podcasts :Le podcast de Fabrice Midal (toutes mes vidéos en version audio) :

Stephan le Roux, bedryfsbestuurder van Amanteco, gesels oor die storie agter Amanteco en die amandelbedryf in Suid-Afrika. Volg RSG Geldsake op Twitter

Stephen Grootes speaks to Reni le Roux. Sales and Marketing Manager @ AMANTECO, Food Safety Co-ordinator, Founder Of The Almond Girl about her inspiring career journey and how her family turned a dream into South Africa’s first commercial almond farm, now a thriving business in the Little Karoo. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

durée : 00:44:58 - Les Nuits de France Culture - par : Albane Penaranda - Cinquième et dernier volet de la série "Grands savants, grands médecins", cette fiction radiophonique redonne vie à Émile Roux, le très proche et peut-être le plus précieux disciple et collaborateur de Louis Pasteur, un monument de l'histoire scientifique et médicale bien que resté très discret. - réalisation : Rafik Zénine

In today's BizNews Briefing, Alec Hogg speaks with Sakeliga CEO Piet le Roux about the organisation's four-year battle in the failing municipality, Ditsobotla. Le Roux explains how Sakeliga is forcing accountability by targeting officials personally liable for governance collapse, offering a hopeful new model for communities trapped in dysfunction.

In this Director's Cut, Alec Hogg speaks to Sakeliga CEO Piet le Roux, who explains how his organisation is holding government accountable for collapsing municipalities. From landmark court battles to innovative “state-proofing” projects, Sakeliga is challenging corruption, mismanagement, and state overreach - proving that business and civil society can rebuild South Africa where government has failed.

South of Midnight Part 3: ROUX WAS AHMED BEST?! Square Roots - Episode 488 Quest Log: 0:16:57 Level Up: 1:12:28 Somehow, throughout this series, Jim, Matt and Vanessa never mentioned that the character Roux from Compulsion Games was played by Jar-Jar Binks, everyone's favourite Star Wars character. Or his actor, anyway, Ahmed Best. Also: * Matt and Jim Don't Know Where the Rockstar Headquarters Are * Jim's Famous Matt Character * A Scardey-Cat Fish * Back to the Future is a Christmas Movie * Onlyh Vanessa Knows the Facts of Life Theme This Week: Finish the game! Next Week: Defeat Hooktail in Paper Mario: The Thousand Year Door Our Patreon: http://patreon.com/squarerootspodcast Thanks to Steven Morris for his awesome theme! You can find him at: https://bsky.app/profile/stevenmorrismusic.bsky.social and https://www.youtube.com/user/morrissteven Contact Square Roots! Twitter: @squarerootspod Facebook: https://www.facebook.com/groups/486022898258197/ Email: squarerootspodcast (at) gmail (dort) com

Chez les personnes rousses, la différence ne se limite pas à la couleur flamboyante des cheveux. Elle se joue aussi dans les profondeurs de leur génétique — et jusqu'à la salle d'opération. Depuis une vingtaine d'années, les anesthésistes observent un phénomène fascinant : les roux nécessitent souvent une dose d'anesthésiant plus élevée que la moyenne. En général, entre 10 et 20 % de plus.Pourquoi ? La réponse se cache dans un gène bien particulier : le MC1R.Ce gène, situé sur le chromosome 16, code pour un récepteur impliqué dans la production de mélanine, le pigment qui colore notre peau et nos cheveux. Chez les personnes rousses, une mutation du MC1R empêche ce récepteur de fonctionner normalement. Résultat : le corps fabrique moins d'eumélanine (pigment brun-noir) et davantage de phéomélanine (pigment rouge-orangé). Mais cette mutation n'a pas qu'un effet esthétique : elle influence aussi la chimie du cerveau.Des études menées notamment à l'Université de Louisville et publiées dans Anesthesiology ont montré que cette mutation modifie la sensibilité à certaines substances. Les porteurs de la mutation MC1R seraient plus résistants aux anesthésiques locaux et plus sensibles à la douleur thermique. En d'autres termes, ils ressentent davantage la douleur et répondent moins efficacement à certains analgésiques, comme la lidocaïne ou le desflurane.Les mécanismes exacts ne sont pas encore complètement élucidés, mais tout indique que le gène MC1R interagit indirectement avec les récepteurs opioïdes et les voies dopaminergiques du cerveau, impliqués dans la perception de la douleur. Ce dérèglement explique pourquoi les anesthésistes ajustent leurs doses : ignorer cette particularité pourrait exposer le patient roux à un réveil prématuré ou à une douleur insuffisamment contrôlée pendant l'intervention.Conscients de ces spécificités, de plus en plus de médecins adaptent leur protocole en conséquence, notamment pour les anesthésies générales et locales. Cela ne signifie pas que les roux soient « difficiles à endormir », mais plutôt que leur seuil de réaction diffère.Ainsi, derrière la singularité de leur couleur de cheveux se cache une particularité biologique encore mal connue du grand public : les roux ne sont pas seulement uniques par leur apparence, mais aussi par la manière dont leur organisme réagit à la douleur et aux médicaments destinés à la calmer. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Dans cet épisode, je reçois Danielle Héroux, la mère de Alexandre Cazes, autrement appelé Alpha-02, était derrière l'un des plus importants sites sur le dark web du monde (Alpha-Bay). Arrêté par le FBI en Thaïlande en 2017, Alexandre est retrouvé mort en cellule peu après. Rongée par les doutes, Danielle retourne en Thaïlande pour rapatrier son fils et mener sa propre enquête. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Welcome to the (Not So) New 52, a real-time retrospective of DC Comics' New 52 imprint! Discussed this week: 0:00:00 - Intro 0:02:58 - Justice League #43 (Geoff Johns and Jason Fabok) 0:13:24 - Secret Six #5 (Gail Simone and Dale Eaglesham) 0:25:31 - Wonder Woman #43 (Meredith Finch and Ian Churchill) 0:35:09 - Robin: Son of Batman #3 (Patrick Gleason) 0:46:26 - Green Lantern: The Lost Army #3 (Cullen Bunn and Jesús Saíz, Cliff Richards) 0:57:41 - Harley Quinn / Power Girl #3 (Amanda Conner, Jimmy Palmiotti, Justin Gray and Stéphane Roux, Elliot Fernandez, Moritat) 1:06:44 - Black Canary #3 (Brendan Fletcher and Annie Wu) 1:13:44 - Superman / Wonder Woman #20 (Peter Tomasi and Doug Mahnke) 1:24:31 - Doctor Fate #3 (Paul Levitz and Sonny Liew) 1:34:12 - Martian Manhunter #3 (Rob Williams and Eddy Barrows) 1:45:05 - Bizarro #3 (Heath Corson and Gustavo Duarte, Fabio Moon) 1:55:10 - Doomed #3 (Scott Lobdell and Javier Fernandez) 2:05:35 - Next Week's Books patreon: https://www.patreon.com/mildfuzztv twitter: @DCComicsPodcast (Use #New52) discord: https://discord.gg/8fbyCehMTy Other Links: https://linktr.ee/mildfuzz Find out more at https://the-not-so-new-52.pinecast.co

La Intendencia de Montevideo (IM) inició tareas de reacondicionamiento en la Plaza Matriz de la Ciudad Vieja. Los trabajos incluyen el retiro de arbustos altos de los jardines geométricos, que serán reemplazados por plantas de hasta 70 centímetros. Según la comuna, la medida busca mejorar la visibilidad, la seguridad y el mantenimiento del espacio público. Las plantas retiradas serán trasladadas al vivero municipal para su posterior trasplante. La intervención forma parte del plan de revitalización de Ciudad Vieja. Emiliano Cotelo y Romina Andrioli conversaron con Marcelo Roux, director de Espacios Públicos de la IM.

Episode 1: Understanding surrogacy (What it means to carry for another)Relebogile Mabotja speaks to Dr Paul le Roux a Specialist in reproductive medicine about surrogacy and what it means to carry for another. 702 Afternoons with Relebogile Mabotja is broadcast live on Johannesburg based talk radio station 702 every weekday afternoon. Relebogile brings a lighter touch to some of the issues of the day as well as a mix of lifestyle topics and a peak into the worlds of entertainment and leisure. Thank you for listening to a 702 Afternoons with Relebogile Mabotja podcast. Listen live on Primedia+ weekdays from 13:00 to 15:00 (SA Time) to Afternoons with Relebogile Mabotja broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/2qKsEfu or find all the catch-up podcasts here https://buff.ly/DTykncj Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

What is "real" Louisiana cooking? There's Creole, there's Cajun, and what's the difference anyway? However you define it, for many of us, it's simply what your mama used to make that made you feel loved. On this week's show, we meet three Louisiana authors whose cookbooks help tell the authentic story of our state's distinctive cuisine. First, we hear from Eric Cook, the executive chef and owner of two distinguished New Orleans restaurants: Gris-Gris and St. John. Eric talks about the evolution of our traditional local fare – many examples of which can be found in his cookbook, Modern Creole: A Taste of New Orleans Culture and Cuisine. Eric shares his secrets to success with dishes such as crab and shrimp stew, wild duck cassoulet, and even his mama's chicken and dumplings. Next, we welcome food writer and culinary historian Marcelle Bienvenu, who has reported on Cajun and Creole cooking for half a century. She shares her expert knowledge and talks about the fifth edition of her classic cookbook, Who's Your Mama, Are You Catholic, and Can You Make a Roux? Finally, for 125 years, Vaucresson Sausage Company has produced its beloved brand in New Orleans' Seventh Ward. In her debut cookbook, Creole Made Easy, co-owner Julie Vaucresson shares recipes and stories both from her illustrious family of origin and the family she married into. For more of all things Louisiana Eats, be sure to visit us at PoppyTooker.com.

What is "real" Louisiana cooking? There's Creole, there's Cajun, and what's the difference anyway? However you define it, for many of us, it's simply what your mama used to make that made you feel loved. On this week's show, we meet three Louisiana authors whose cookbooks help tell the authentic story of our state's distinctive cuisine. First, we hear from Eric Cook, the executive chef and owner of two distinguished New Orleans restaurants: Gris-Gris and St. John. Eric talks about the evolution of our traditional local fare – many examples of which can be found in his cookbook, Modern Creole: A Taste of New Orleans Culture and Cuisine. Eric shares his secrets to success with dishes such as crab and shrimp stew, wild duck cassoulet, and even his mama's chicken and dumplings. Next, we welcome food writer and culinary historian Marcelle Bienvenu, who has reported on Cajun and Creole cooking for half a century. She shares her expert knowledge and talks about the fifth edition of her classic cookbook, Who's Your Mama, Are You Catholic, and Can You Make a Roux? Finally, for 125 years, Vaucresson Sausage Company has produced its beloved brand in New Orleans' Seventh Ward. In her debut cookbook, Creole Made Easy, co-owner Julie Vaucresson shares recipes and stories both from her illustrious family of origin and the family she married into. For more of all things Louisiana Eats, be sure to visit us at PoppyTooker.com.

Entrevista Marcelo Roux - Director de Espacios Públicos by En Perspectiva

China se groeiende aptyt vir Namibiese beesvleis kan die vraag tot 20 000 ton per maand laat styg, maar kenners waarsku dat produksie nie tred sal kan hou nie. In 'n onderhoud met Kosmos 94.1 Nuus het landboukenner Wallie Roux gesê Namibië, die droogste Afrika-land suid van die Sahara, staar natuurlike beperkings in die gesig ten opsigte van hoeveel dit kan produseer. Die land se afhanklikheid van reënval beteken dat die uitbreiding van beesvleisproduksie met stygende koste sal gepaardgaan. Roux het meer.

Prof. André Roux, ekonoom en programhoof van Toekomsstudies by die Stellenbosch Sakeskool, gesels oor sy agtergrond, loopbaan, die industrie waarin hy is, en wat hy doen om te ontspan. Volg RSG Geldsake op Twitter

Education activist Vanessa le Roux chats to John Maytham about the victim of bullying at Milnerton High School, and the steps being taken to get justice for the learner Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Ecoutez RTL Matin avec Thomas Sotto du 21 octobre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

This week, it's all smoke and discipline with the pitmaster–entrepreneur himself, Chef Charlie Mckenna. He's the founder behind Lillie's Q, known for Memphis in May-winning pork shoulder, as well as his regionally faithful Lillie's Q sauces and rubs. He tells us about the journey from CIA grad and Michelin-line cook to Chicago barbecue, and what his Air Force family's “six Ps” instilled in his leadership. Plus: how CPG realities differ from fine dining, how Roux lets him serve his favorite dishes, the secret salsa at Tony's Burrito Mex, and so much more!

Her name is Paige Roux, but you may know her as Some Chick Who Shoots!  Paige is a nationally recognized firearms instructor for women and she empowers first-time gun owners to feel confident, safe, and prepared.  She joins us to share not only her personal journey and passions, but also to discuss a wide variety of topics surrounding gun ownership, firearm safety, learning to shoot, 2nd Amendment advocacy and more!  Paige provides valuable insight and perspectives for not just female gun owners, but also within family dynamics and preserving safe firearm practices in the home. This episode breaks the mold of our normal show by tapping into another important genre of self-defense and our right to bear arms!Fall Obsession Podcast is sponsored by:Hoot Camo Company (https://hootcamo.com/)Bear River Archery (https://www.bearriverarchery.com/)Trophy Edits (https://trophyedits.com/?ref=fallobsession)The Outdoor Call Radio App (https://www.theoutdoorcallradio.com/)

Sleeve, bypass, or something new – which surgery really dominates the day?  This Bariatric Surgery Journal Club dives into the debate over which bariatric operation is best. We compare the outcomes of the gastric bypass, sleeve gastrectomy, and the newer Sadie procedure, exploring how bypass may have an edge in long-term diabetes remission and weight loss.  We also discuss revisional options for failed sleeves and the importance of matching the patient to the right operation for their specific needs. Hosts: - Matthew Martin, trauma and bariatric surgeon at the University of Southern California/Los Angeles General Medical Center (Los Angeles, California)  - Adrian Dan, bariatric and MIS surgeon, program director for the advanced MIS bariatric and foregut fellowship at Summa Health System (Akron, Ohio) - Crystal Johnson Mann, bariatric and foregut surgeon at the University of Florida (Gainesville, Florida) - Katherine Cironi, general surgery resident at the University of Southern California/Los Angeles General Medical Center (Los Angeles, California) Learning objectives: - Contrast the outcomes of Roux-en-Y gastric bypass, sleeve gastrectomy, and revisional options such as the single-anastomosis duodeno-ileal bypass (SADI) - Article #1: Hauge 2025, Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple blind, randomized controlled trial https://pubmed.ncbi.nlm.nih.gov/40185112/ - Describe the design and unique triple-blind methodology of a single-center randomized trial comparing bypass and sleeve in patients with obesity and type 2 diabetes.  - Interpret the clinical relevance of the 5-year outcomes, including 63% diabetes remission with bypass vs 30% with sleeve.  - Examine secondary outcomes such as weight loss and cholesterol reduction, which favored bypass over the sleeve - Formulate patient-centered strategies for selecting bypass versus sleeve in populations with advanced metabolic disease, balancing efficacy with patient preference  - Article #2: The By-Band-Sleeve Collaborative Group 2025, Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicenter, open-label, three-group, randomized controlled trial https://pubmed.ncbi.nlm.nih.gov/40179925/ - Summarize the findings of this multi-center, open-label randomized controlled trial of over 1,300 patients comparing bypass, sleeve, and gastric banding at 5 years - Discuss the relative weight loss outcomes: 67% excess weight loss for bypass, 63% for sleeve, and 28% for adjustable gastric band - Evaluate the improvements in diabetes remission, hypertension control, and lipid management with bypass and sleeve compared to banding. - Analyze the declining role of gastric banding in modern bariatric surgery, while acknowledging its benefits compared to no weight loss treatment - Article #3: Thomopoulos 2024, Long-term results of Roux-en-Y gastric bypass (RYGB) versus single anastomosis duodeno-ileal bypass (SADI) as revisional procedures after failed sleeve gastrectomy: a systematic literature review and pooled analysis https://pubmed.ncbi.nlm.nih.gov/39579238/ - Compare long-term outcomes of bypass versus SADI after failed sleeve gastrectomy, based on pooled analysis of over 1,000 patients  - Interpret the trade-offs: SADI provides greater weight loss and metabolic improvements, but carries a higher risk for malnutrition and fat-soluble vitamin deficiencies  -  Develop strategies for preoperative counseling, nutritional supplementation, and close long-term monitoring, particularly for patients undergoing SADI - Individualize decision-making for revisional surgery, considering factors such as patient goals, comorbidity burden, prior anatomy, BMI, and reliability with follow-up - Evolving revisional strategies will influence the next decade of bariatric surgical innovation   - Overall, bariatric surgery consistently improves weight, diabetes control, and cardiovascular risk. - The procedure of choice should be tailored to the patient through detailed discussion between surgeon and patient, aligning clinical evidence with patient goals and risks.   References 1.     Wågen Hauge J, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2025 May;13(5):397-409. doi: 10.1016/S2213-8587(24)00396-6. Epub 2025 Apr 1. PMID: 40185112. https://pubmed.ncbi.nlm.nih.gov/40185112/ 2.     By-Band-Sleeve Collaborative Group. Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025 May;13(5):410-426. doi: 10.1016/S2213-8587(25)00025-7. Epub 2025 Mar 31. PMID: 40179925. https://pubmed.ncbi.nlm.nih.gov/40179925/ 3.     Thomopoulos T, Mantziari S, Joliat GR. Long-term results of Roux-en-Y gastric bypass (RYGB) versus single anastomosis duodeno-ileal bypass (SADI) as revisional procedures after failed sleeve gastrectomy: a systematic literature review and pooled analysis. Langenbecks Arch Surg. 2024 Nov 23;409(1):354. doi: 10.1007/s00423-024-03557-9. PMID: 39579238; PMCID: PMC11585492. https://pubmed.ncbi.nlm.nih.gov/39579238/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Dr. Cecil Wood discusses the RadioGraphics article “Internal Hernias after Roux-en-Y Gastric Bypass: Clues to a Challenging Diagnosis”, highlighting why these complex and potentially dangerous complications remain difficult to identify. He explains surgical anatomy, risk factors, and key CT signs, offering a systematic approach to improve diagnostic accuracy for radiologists. Internal Hernias after Roux-en-Y Gastric Bypass:Clues to a Challenging Diagnosis. Wood et al. RadioGraphics 2025; 45(10):e240197.  

South Africa is running out of time. Load shedding, unemployment, corruption, crumbling infrastructure - the challenges keep stacking up. But can business step in where government is failing and help put the country back on solid footing? Join us for this urgent conversation with moderator Justice Malala, political economist Moeletsi Mbeki, corporate leader Bonang Mohale, founder of ActionSA Herman Mashaba and CEO of Sakeliga, Piet le Roux. The Burning Platform

Dans le film Muganga - Celui qui soigne réalisé par Marie-Hélène Roux et dont la sortie est prévue le 24 septembre 2025 au cinéma, l'acteur ivoirien Isaach de Bankolé incarne le Dr Mukwege «L'homme qui répare les femmes» victimes de violences sexuelles à l'est de la République Démocratique du Congo. Le film raconte la rencontre du Dr Mukwege avec Guy Cadière, chirurgien belge qui va redonner un souffle nouveau à son engagement. Bande-annonce du film Papa Wemba - Phrase Retrouvez la playlist officielle de RFI Musique.

Dans le film Muganga - Celui qui soigne réalisé par Marie-Hélène Roux et dont la sortie est prévue le 24 septembre 2025 au cinéma, l'acteur ivoirien Isaach de Bankolé incarne le Dr Mukwege «L'homme qui répare les femmes» victimes de violences sexuelles à l'est de la République Démocratique du Congo. Le film raconte la rencontre du Dr Mukwege avec Guy Cadière, chirurgien belge qui va redonner un souffle nouveau à son engagement. Bande-annonce du film Papa Wemba - Phrase Retrouvez la playlist officielle de RFI Musique.

In this episode of Crossing Faiths, John Pinna speaks with Eric Roux from the United Religions Initiative (URI) about his personal and professional journey in interfaith collaboration and religious freedom advocacy. Roux recounts how his work began by defending his own faith, Scientology, against discrimination in France, but evolved as he recognized the greater power and necessity of working alongside other religious communities to support each other. They discuss the complex landscape of religious freedom in Europe and explore the unique, grassroots structure of URI, which fosters "Cooperation Circles" worldwide to build relationships and tackle local issues—from environmentalism to violence prevention—through collaborative action. Key themes include the effectiveness of diverse communities defending one another, the importance of moving beyond dialogue to tangible cooperation, and the belief that building genuine relationships is the most effective way to create a more peaceful world focused on shared goals and human dignity. Eric Roux has devoted himself to the service of his faith and to the universal cause of freedom of religion for more than three decades. He became a member of the clergy of the Church of Scientology in 1993 and was ordained as a minister of religion shortly thereafter. From the earliest days of his ministry, he demonstrated a strong commitment to both spiritual outreach and humanitarian initiatives. Recognizing that meaningful progress requires cooperation across faith traditions, Eric Roux co-founded the FoRB Roundtable Brussels EU. This innovative platform regularly brings together over one hundred governmental and non-governmental organizations to exchange insights, forge alliances, and develop joint strategies for the protection and promotion of religious rights. Through regular meetings, the Roundtable has become a crucible for collaborative policymaking, leading to tangible improvements in legal safeguards for persecuted minorities. His work has earned him international acclaim as a champion of freedom of religion and belief. In recognition of his skills in consensus-building and his unwavering dedication to human dignity, Eric Roux was recently elected Chair of the Global Council of the United Religions Initiative (URI), the world's largest grassroots network dedicated to interreligious cooperation. As Chair, he now guides URI's strategic vision, supporting a myriad of local multifaith groups and grassroots projects.

Piet le Roux, uitvoerende hoof van Sakeliga, bespreek 'n saak wat as 'n toetssaak oor onteiening sonder vergoeding dien. Volg RSG Geldsake op Twitter

Sakeliga has become involved in a previously low-profile seven-year legal battle over a 34-hectare farm worth an estimated R60m, which was expropriated for nil compensation by the ANC/EFF controlled Ekurhulen Metro. Here's Sakeliga's CEO Piet le Roux who says the case has massive political, economic and social implications.

Denis Mukwege, médecin congolais et futur Prix Nobel de la paix, soigne — au péril de sa vie — des milliers de femmes victimes de violences sexuelles en République démocratique du Congo. Sa rencontre avec Guy Cadière, chirurgien belge, va redonner un souffle à son engagement. Film : Muganga – Celui qui soigne. Invitées : - Marie-Hélène Roux, réalisatrice - Manon Bresch, actrice (Maïa Cadière) - Déborah Lukumuena, actrice (Busara).

durée : 00:18:42 - Nouveau Premier ministre, pandas roux et temps d'écran - Sébastien Lecornu est devenu le nouveau Premier ministre, comment se passe la rentrée scolaire à Gaza et un dossier sur les pandas roux : c'est le menu du nouvel épisode de "Salut l'info !". Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Débatteurs du soir : -Jules Torres, journaliste politique au JDD -Sarah Saldmann, avocate Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Die bespreking rondom die land se groenskemas duur voort. Die landboukundige Wallie Roux glo dat die ontbinding van Agribusdev, weens langdurige finansiële probleme en wanbestuur, 'n stap in die regte rigting was. Dit baan moontlik die weg vir die herlewing en uitbreiding van die groenskemas. In 'n onderhoud met Kosmos 94.1 Nuus het Roux die belangrikheid van publiek-private vennootskappe beklemtoon om die sukses van hierdie inisiatiewe te verseker.

Thank you Sabrina 'The Unyielding' Tran, OMS IV, for developing this podcast topic! Thank you Cynthia Sharma, OMS IV, for being a great sidekick!This podcast starts with high yield information about SSRI discontinuation syndrome and Lithium toxicity. The discussion then dives into the nuances of how either a Roux-and-Y or Sleeve Gastrectomy may affect blood levels of various medications. This is a technical discussion that has great information! We enjoyed our discussion and hope you do too!Thank you to the physicians that have blazed the podcast pathway over the last half decade. Thank you to the new students that carry the torch! Thank you to the immortal Jordan Turner for creating the perfect bumper music! Most of all, thank you to everybody that listens in and learns with us.

Epi: 324 Welcome back, OSLP family! In this powerful episode of Our Sleeved Life Podcast, we welcome Rob Rafanan from The Weighting Table—aka @theweightingtable, @weightinginvain, and @trans4m.bariatric.bodybuilding—to share his raw and inspiring bariatric journey. Rob opens up about his personal struggles with morbid obesity, chronic health conditions like hypertrophic cardiomyopathy, and how hitting nearly 400 pounds forced him to reevaluate everything—from his physical health to being a present father.We dive deep into:How Rob battled hypertension, sleep apnea, and back pain while trying to maintain a careerWhat it was like living as a "present but absentee" dad and how that shifted after surgeryWhy he finally said yes to Roux-en-Y (RNY) gastric bypass surgery after years of failed attempts to lose weight on his ownThe moment a chiropractor changed his life with one simple, hard questionHis journey through Canada's bariatric surgery systemLosing over 100 pounds with cycling and dealing with setbacks like tendonitisHow mindset coaching, therapy, and practicing gratitude and mindfulness helped reframe his post-op journeyWhy emotional eating isn't shameful—and how to build healthier coping tools that work long-termThe role of community support, Radical Body Transformation prep, and learning how to balance discipline with real lifeRob and Mel discuss everything from post-op plastic surgery to how guilt and generational trauma affect weight regain and emotional eating triggers. You'll walk away with real-life strategies for managing setbacks, building resilience, and redefining your relationship with food.

Discover Lafayette welcomes Marcelle Bienvenu, cookbook author and food writer who has been preparing Cajun and Creole dishes since the 1960s. A St. Martinville native, she still lives there with her husband, Rock Lasserre. Marcelle has written about Creole and Cajun cooking for The Times-Picayune, Time-Life Books, and has been featured in Garden & Gun, Food & Wine, Saveur, Southern Living, Redbook, The New York Times, Louisiana Life, and Acadiana Profile. She authored Who's Your Mama? Are You Catholic and Can You Make a Roux?, as well as Who's Your Mama? The Sequel, and Cajun Cooking for Beginners. She co-edited Cooking Up a Storm: Recipes Lost and Found from The Times-Picayune of New Orleans, which was nominated for a James Beard Award in 2009. Marcelle worked with Emeril Lagasse for 15 years and coauthored several cookbooks with him, including Louisiana Real & Rustic, Emeril's Creole Christmas, Emeril's TV Dinners, and Every Day's a Party. She also owned and operated the beloved restaurant Chez Marcelle in Broussard, at the former Billeaud Family Plantation site. She has worked at legendary restaurants including Commander's Palace and K-Paul's Louisiana Kitchen in New Orleans, and taught for 11 years at the Chef John Folse Culinary Institute at Nicholls State University. Growing Up in St. Martinville “When I was a youngster, it was idyllic. You could ride your bike anywhere. Nobody cared where you were going. We could go around the block and ask all the ladies, ‘What do you have for supper tonight?' If I liked hers better than mine, I could stay with her. Everybody on our block was related.” Her father's family owned The Teche News, and she grew up folding papers and helping with printing: “Besides the newspaper, Daddy did wedding invitations, football programs. I used to hate it because my hands were always full of ink… Mama would fix the sandwiches at the newspaper office because we never went home on paper day until late. The ink was all over your bread.” She credits her early love of cooking to meals at family camps on Vermilion Bay: "My father was a Boy Scout leader, and we had a camp at Granddad's on Vermilion Bay, at Sycamore Point, and we had one in the Basin. A lot of our meals were cooked on an open fire wood bar. And I thought that was absolutely fabulous. So I would sit at my daddy's elbow with his beer. I was beer holder. I would say, shouldn't you go medium low? You don't have a dial, you'd have to move it. I became infatuated with that. I thought that was just marvelous. “We were laughing the other day about when we were little, nobody said, oh, we're going to have Cajun food. Are we going to New Orleans? Can we have Creole food? We never would. Nobody ever said that." An interesting side note: Marcelle is the aunt of Louisiana Gov. Jeff Landry. His mother and Marcelle's sister, Edna Bienvenu Landry, died in 2019. Our governor also unfortunately recently lost his father, architect and business owner, Al James Landry, on July 30, 2025. The Start of a Culinary Career In 1971, while working at The Times-Picayune, Marcelle met the Time-Life Books crew. “They were thinking of doing a book on Acadian Creole cooking… We were supposed to be only a chapter in the Southern book, but we ended up with a whole book.” Working with the Brennans and legendary chef Paul Prudhomme shaped her approach: “He really brought Cajun cooking up to another level… It was absolutely wonderful to see them marrying those two cuisines to see what they came up with." Before Prudhomme joined Commander's Palace, no one in New Orleans was serving chicken and andouille sausage gumbo. Chez Marcelle Marcelle's uncle offered to finance a restaurant in Broussard, and they transformed the old Billeaud Plantation home: “We did fabulously for almost four years and then the whole business… the oil industry crashed. It happened so fast my CPA called to ask if we had closed.

Our Sponsor, FLESHLIGHT, can help you reach new heights with your self-pleasure. Fleshlight is the #1 selling male sex toy in the world. Looking for your next pocket pal? Save 10% on your next Fleshlight with Promo Code: 10PRIVATE at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fleshlight.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. For the 220th episode of Private Parts Unknown, host Courtney Kocak welcomes Marika Leila Roux, a Berlin-based Shibari practitioner & the co-founder of Shibari Study, the leader in online rope education. Shibari is Japanese rope bondage, a form of BDSM. The word broadly means "binding" or "tying." It originated from Hojo-jutsu, a torturous method of restraining captives, before morphing into the erotic bondage Kinbaku in the late 19th and early 20th centuries. Marika shares her personal journey with Shibari, and we get into the origins and how it relates to Western BSDM practices, how you can practice by yourself with self-tying or solo tying, the benefits, including mindfulness and meditation, the nuances in terminology between rigger vs. rope top and rope model vs. rope bottom, misconceptions about the power dynamics, the difference between power and control, and so much more. For more Shibari Study: Try Shibari Study ⁠shibaristudy.com⁠ Follow Shibari Study on Instagram ⁠@shibari.study⁠ Psst, Courtney has an 0nIyFan$, which is a horny way to support the show: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/cocopeepshow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Private Parts Unknown is a proud member of the Pleasure Podcast network. This episode is brought to you by: VB Health offers doctor-formulated sexual health supplements designed to elevate your sex life. Their lineup includes Soaking Wet, a blend of vitamins and probiotics that support vaginal health; Load Boost, which promotes male fertility and enhances semen volume and taste; and Drive Boost, formulated to increase libido and sexual desire for all genders. Visit ⁠⁠⁠vb.health⁠⁠⁠ and use code PRIVATE for 10% off. I'm OBSESSED with the ⁠⁠Sleep Boost melatonin gummies⁠⁠ from VB Health. Visit ⁠⁠vb.health⁠⁠ and use code PRIVATE for 10% off. Our Sponsor, FLESHLIGHT, can help you reach new heights with your self-pleasure. Fleshlight is the #1 selling male sex toy in the world. Looking for your next pocket pal? Save 10% on your next Fleshlight with Promo Code: 10PRIVATE at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fleshlight.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. STDCheck.com is the leader in reliable and affordable lab-based STD testing. Just go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ppupod.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, click STDCheck, and use code Private to get $10 off your next STI test. Explore yourself and say yes to self-pleasure with Lovehoney. Save 15% off your next favorite toy from Lovehoney when you go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠lovehoney.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and enter code AFF-PRIVATE at checkout. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/PrivatePartsUnknownAds⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you love this episode, please leave us a 5-star rating and sexy review! Psst... sign up for the Private Parts Unknown newsletter for bonus content related to our episodes! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠privatepartsunknown.substack.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Let's be friends on social media! Follow the show on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@privatepartsunknown⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and Twitter ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@privatepartsun⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Connect with host Courtney Kocak ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@courtneykocak⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Instagram and Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textRiley's doctor recommended bariatric surgery as the solution to their health concerns, but when Riley came to me for advice, I realized they hadn't been told about the real risks. From anastomosis leaks with 15% mortality rates to spontaneous bowel perforations years later, the complications of weight loss surgery extend far beyond what most patients are counseled about. In this episode, I walk through the evidence-based risks that every patient deserves to know before making this life-altering decision, because informed consent requires the whole truth. If you or someone you know is considering weight loss surgery, then be sure to send them a link to this episode!References:Lim, Robert et al. “Early and late complications of bariatric operation.” Trauma surgery & acute care open vol. 3,1 e000219. 9 Oct. 2018Silva, Ana Flávia da et al. “Risk factors for the development of surgical site infection in bariatric surgery: an integrative review of literature.” Revista latino-americana de enfermagem vol. 31 (2023)Complications of bariatric surgery: presentation and emergency management--a review.” Annals of the Royal College of Surgeons of England vol. 91,4 (2009): 280-6.Benotti, Peter et al. “Risk factors associated with mortality after Roux-en-Y gastric bypass surgery.” Annals of surgery vol. 259,1 (2014): 123-30. Coupaye, Muriel et al. “Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery vol. 13,4 (2017): 681-685 Husain, Syed et al. “Small-bowel obstruction after laparoscopic Roux-en-Y gastric bypass: etiology, diagnosis, and management.” Archives of surgery (Chicago, Ill. : 1960) vol. 142,10 (2007): 988-93 Seeras K, Acho RJ, Lopez PP. Roux-en-Y Gastric Bypass Chronic Complications. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519489/Got a question for the next podcast? Let me know! Connect With Me FREE GUIDES: evidence-based, not diet nonsense NEWSLETTER: Life-changing insights straight to your inbox UNSHRINKABLE: Find out why your body is not designed to shrink MASTERCLASSES: All the evidence doctors should give you NO WEIGH PROGRAM: Join the revolution against weight-loss lies THE WEIGHTING ROOM: A community where authenticity thrives and every voice matters CONSULTATION: For the ultimate transformation in your healthcare journe Find me on Instagram, YouTube, and LinkedIn.

Givaudan VP Perfumer Rodrigo Flores-Roux generously returns to the Perfume Room to offer a definitive roadmap to the past, present, and future of perfume. Bookmark this ep. You'll come back to it. Rodrigo is a fragrance genealogist of sorts, tracing your favorite perfumes' parents, grandparents, and great-grandparents. He offers a rare perfumer's POV on the current landscape: What's trending? Why? What even qualifies as a trend? Should we care? And what's happening in the world today that will shape how fragrance smells tomorrow?WATCH THE FLORSTALGIA PANEL (coming this Fri)LISTEN TO EP. 136 (linked below)THANK YOU TO THIS MONTH'S SPONSOR THE RACONTEUR! 10% off full bottles of The Raconteur @ Stéle: code 'emma10'FRAGS MENTIONED:Sol de Janeiro, Phlur, Burberry Goddess, 27 87 Hakuna Matata, Mary Kay Velocity, Marc Jacobs Daisy Wild, Vacation Inc, Arquiste Tropical, Cire Trudon Merida, ARQUISTE Esencia de El Palacio Guayabos, Chanel No. 5, Guerlain Shalimar, Lanvin Arpège, Schiaparelli Shocking, Robert Piguet Bandit, Balmain Vent Vert, Carven Ma Griffe, Givenchy L'Interdit, Nina Ricci L'Air du Temps, Madame Rochas, Rabanne Calandre, Eau de Lancome, Eau de Patou, Eau de Guerlain, Estée Lauder Estée Super, Revlon Charlie, YSL Opium, Estée Lauder Youth Dew, Balenciaga Prelude, Estée Lauder Cinnabar, Fendi, Giorgio, Dior Poison, Ralph Lauren Polo, Guy Laroche Drakkar Noir, Davidoff Cool Water, New West, Calvin Klein Escape, Issey Miyake L'Eau D'Issey, Mugler Angel, Tom Ford Oud Wood, Donna Karan Black Cashmere, Clinique Happy, Isabell Calla, Ungaro Diva, Florstalgia: Violet, Carnation; YSL Paris, Eauso Vert Fruto Oscuro, Le Galion Bourrasque, Thom Browne: Vetyver & Brut, Vetyver & Rose; Xinu: OroNardo, Copala; ARQUISTE: A Grove By The Sea, Tropical; Roberto Greco Porter Sa Peau

In this conversation, Amore Roux shares lessons from her personal healing journey—from navigating addiction to creating a supportive space for women. If you're facing burnout, emotional pain, or just want to live more authentically, this episode offers relatable insights and steps toward lasting transformation. No filters—just real stories and meaningful reflections.

Brea and Mallory recommend books about journeys! Plus they interview Madeleine Roux and solve a reader problem about getting triggered by books. Email us at readingglassespodcast at gmail dot com!Reading Glasses MerchRecommendations StoreSponsors -Pair Eyewearwww.paireyewear.comCODE: GLASSESAura Frameswww.auraframes.comCODE: GLASSESLinks -Reading Glasses Facebook GroupReading Glasses Goodreads GroupAmazon Wish ListNewsletterLibro.fmTo join our Discord channel, email us proof of your Reading-Glasses-supporting Maximum Fun membership!www.maximumfun.org/joinMadeleine RouxA Girl Walks into the Forest Books Mentioned -Clean by Alia Trabucco Zeran, translated by Sophie HughesA Letter from the Lonesome Shore by Sylvie CathrallMigrations by Charlotte McConaghyThe Marrow Thieves by Cherie DimalineThe Pairing by Casey McQuistonThe Cautious Traveler's Guide to the Wastelands by Sarah BrooksI'm Starting to Worry about This Black Box of Doom by Jason ParginThe Unlikely Pilgrimage of Harold Fry by Rachel JoyceSurvivor Song by Paul TremblayPeaces by Helen OyeyemiJames by Percival EverettStation Eleven by Emily St. John MandelThe Memory Police by Yoko OgawaThe Bloody Chamber by Angela Carter